Exicure, Inc. (XCUR) - Form 8-K Summary
Business Context and Reporting Period
Date of Report: August 2, 2021
Company: Exicure, Inc.
Event: Entry into a Material Definitive Agreement (Item 1.01)
Counterparty: Ipsen Biopharm Limited ("Ipsen")
On July 30, 2021, Exicure entered into a Collaboration, Option and License Agreement with Ipsen. The agreement grants Ipsen exclusive access and options to license spherical nucleic acid (SNA) based therapeutics for two specific programs: Huntington's Disease and Angelman Syndrome.
Key Financial Metrics and Deal Terms
This filing details a strategic partnership rather than a standard financial performance report. Key financial terms include:
- Upfront Payment: $20 million payable to Exicure upon execution.
- Option Exercise Fees:
- $10 million per program if exercised after candidate selection.
- $25 million per program if exercised after the first option period but prior to IND filing.
- Pre-clinical Milestones: $5 million per program upon achievement, regardless of option exercise.
- Development and Regulatory Milestones: Up to $180 million aggregate if both options are exercised (triggered by clinical trial initiation and marketing application filings).
- Commercial Milestones: Up to $762 million aggregate if both options are exercised (triggered by first commercial sale and sales thresholds).
- Royalties: Tiered royalties ranging from mid-single digits to mid-teens on future net product sales.
Note: The filing does not provide current revenue, profit, cash flow, or debt figures for the company.
Material Changes and Responsibilities
The agreement establishes a clear division of financial responsibility for development:
- Exicure Responsibilities: Solely responsible for all costs and expenses through the selection of SNA therapeutic candidates.
- Ipsen Responsibilities: Responsible for all costs to enable the first filing of an Investigational New Drug (IND) application. If an option is exercised, Ipsen assumes responsibility for further development and commercialization.
A portion of payments received by Exicure will be distributed to Northwestern University pursuant to existing license agreements.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The agreement provides a potential pathway for significant future revenue contingent on the successful development of candidates for Huntington's Disease and Angelman Syndrome. The deal structure allows Exicure to de-risk early-stage discovery costs while retaining upside potential through milestones and royalties.
Risks and Contingencies:
- Option Exercise Risk: Significant milestone payments are contingent on Ipsen exercising its options, which is not guaranteed.
- Development Risk: Milestones depend on the successful achievement of pre-clinical, clinical, and regulatory endpoints.
- Termination: The agreement includes customary termination provisions for breach or bankruptcy. If Exicure terminates for Ipsen's breach, all licenses granted to Ipsen will terminate.
- Intellectual Property: The agreement involves sublicensing intellectual property licensed from Northwestern University, subject to specific survival clauses detailed in a Side Letter.
Investor Verification Checklist
- Verify the receipt of the $20 million upfront payment in the next quarterly financial report (10-Q).
- Review the full text of the Collaboration Agreement and Side Letter (to be filed as exhibits to the Q3 2021 10-Q) for specific definitions of "Selection" and "Option Exercise Period."
- Monitor the progress of the Huntington's Disease and Angelman Syndrome programs to assess the likelihood of Ipsen exercising options.
- Confirm the specific percentage of payments allocated to Northwestern University to understand net cash flow impact.
- Assess Exicure's current cash runway to ensure it can fund the discovery phase through candidate selection without additional capital raises.